Logo image
Back
Efficacy of Lacosamide as Adjunctive Therapy in Children With Refractory Epilepsy
Journal article   Peer reviewed

Efficacy of Lacosamide as Adjunctive Therapy in Children With Refractory Epilepsy

William R. Yorns, Divya S. Khurana, Karen S. Carvalho, H. Huntley Hardison, Agustín Legido and Ignacio Valencia
Journal of child neurology, v 29(1)
Jan 2014
DOI: https://doi.org/10.1177/0883073812462887
PMID: 23143718
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

epilepsy antiepileptic lacosamide
Lacosamide is a US Food and Drug Administration (FDA)–approved antiepileptic drug for patients 17 years or older with partial epilepsy. There are sparse data on children. The objective of our study was to evaluate its efficacy/safety in children with refractory epilepsy. Forty children (mean age 14.3 years) were treated with lacosamide at our institution (adjunctive therapy in 36, monotherapy in 4). Fifteen patients had symptomatic focal epilepsy, 2 had cryptogenic focal epilepsy, 20 had symptomatic generalized epilepsy, and 3 had cryptogenic generalized epilepsy. Two had juvenile myoclonic epilepsy and 5 had Lennox-Gastaut syndrome. Forty-two percent had at least >50% reduction in seizure frequency, and 6 became seizure free. Average dose was 7 mg/kg/d and average follow-up was 9.2 months. Responders had a 76.5% mean decrease in seizures. Fifteen children experienced an adverse reaction and 7 discontinued lacosamide (4: Ineffective, I: insurance denial, 1: tremor, 1: behavior). Lacosamide is effective and well-tolerated in children with refractory epilepsy.

Metrics

6 Record Views
37 citations in Web of Science
37 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Clinical Neurology
Pediatrics
Logo image